Thanks Mr K
Indeed there have been many immuno oncolgy deals done at Ph2 stage for that kind of price.
And CAR-T for much higher.
Good to see a base line set.
I do the calcs based on a BCell platform plus an OV platform sold separately that equates to much more than a 16 bagger from here.
40X
However, if both platforms are successful, future revenue sharing deals 50/50 for each rather than outright sale would result in much greater returns
3.4 is pricing in bulldust
-
- There are more pages in this discussion • 25,609 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |